Market Trends of Global Carboprost Tromethamine Industry
This section covers the major market trends shaping the Carboprost Tromethamine Market according to our research experts:
The Postpartum Hemorrhage Treatment Segment is Expected to Hold a Major Market Share in the Carboprost Tromethamine Market
Postpartum hemorrhage is one of the major causes of maternal morbidity and mortality. According to World Health Organisation's data on Maternal, Newborn, Child, and Adolescent Health and Ageing, in 2021, India had the largest number of births in the world with approximately 24,016,020 thousand, followed by China with 15,918,889 thousand. The high birth rate also results in an increase in the number of cases of postpartum hemorrhage. An article published by the BMC Journal of Reproductive Health in March 2022 estimates that postpartum mortality is one of the leading causes of maternal mortality in developing countries, accounting for approximately 25.0-43.0% of total maternal deaths. The article also indicated that the extent of postpartum hemorrhage among mothers after childbirth in Ethiopia is moderately high. Such an increase in cases of postpartum hemorrhage is expected to surge the demand for the treatment, thereby propelling the sale of carboprost tromethamine injections.
An article published in the Tropical Journal of Pharmaceutical Research in May 2020 studied the effects of carboprost tromethamine in the treatment of cesarean-associated postpartum hemorrhage and concluded that carboprost tromethamine prevents postpartum hemorrhage after cesarean section. The study also indicated that it effectively reduces bleeding and promotes uterine involution, with no apparent adverse reactions. Recent research has also focused on the combination therapy of carboprost tromethamine with other drugs for their effect on postpartum hemorrhage. An article published in the journal; Medicine in July 2021 revealed the effectiveness of carboprost tromethamine in combination with Leonurus Japonicus injection for the prevention of postpartum hemorrhage in high-risk pregnant women. The study indicated that the prophylactic use of Leonurus Japonicus Injection in combination with carboprost tromethamine might have a good effect on the prevention of postpartum hemorrhage after childbirth. Research into the use of carboprost tromethamine is of great importance, and the scope of research work being carried out on further therapy is considerable.
These factors are expected to have a significant impact on the growth of the carboprost tromethamine market in the upcoming period.
North America is Expected to Dominate the Carboprost Tromethamine Market
The carboprost tromethamine market is expected to witness significant growth in the North American region during the forecast period.
According to the World Health Organization(WHO) in 2021, the number of births in the United States for the year 2021 is 3,985,712 thousand. A high number of births is associated with an increasing number of cases of postpartum hemorrhage. The number of live births is expected to reach approximately 4,124,888 thousand by 2050. The National Institute for Child Health Quality revealed in April 2022 that approximately 3.0% of births in the United States reported cases of postpartum hemorrhage. These cases represented more than 100,000 births per year. The above source also showed that hospitals might be able to prevent up to 70.0% of bleeding-related obstetric deaths. The right treatment strategies could help reduce maternal mortality in the United States. Carboprost Tromethamine is intended to suppress the effects of postpartum bleeding in pregnant women. Thus, the carboprost tromethamine market is expected to grow in the North American region during the forecast period.
Key product launches, high concentration of market players or manufacturer presence and acquisitions and partnerships between major players, and high pregnancy rates in the United States are some of the factors driving the growth of the carboprost tromethamine market in the country. For example, according to the United Health Foundation America's Health Rankings for 2021, the United States had approximately 30.6% of unintended pregnancies during the year. In addition, increased awareness and advantages of the treatment may increase the use of carboprost tromethamine in the United States. For example, according to an article published in the IOSR Journal of Dental and Medical Sciences in June 2020, carboprost tromethamine was reported to be 84.0-96.0% effective in treating persistent bleeding due to uterine atony and may avoid the need for surgery. Therefore, such a positive result may increase the demand for carboprost Tromethamine in the United States. In addition, the increase in research and development by companies in the clinical stage of new treatments for postpartum hemorrhage is anticipated to fuel the growth of the carboprost tromethamine market in the country.
Therefore, due to the above-mentioned factors, the country is expected to experience a high growth rate during the forecast period. Hence, due to the above-mentioned factors, a high growth rate is anticipated in the country over the forecast period.
